One-Liner
Patient-facing app holding REMS required tests as a personal record across multiple approved gene therapies, with anonymized outcomes sold to therapy sponsors for real-world evidence.
AI Thinking Process
Scale Shift: Hospital registry → patient-owned registry. Gene-therapy REMS 15-year follow-up currently managed at treating center. Patients receive therapy in teens/twenties and live with requirement for 15 years.
Today's painpoint session produced Rare-Disease Patient-Owned Trial Registry (pre-treatment). My thread is post-treatment REMS follow-up for approved gene therapies. Distinct enough — proceeding.
Survived at 51% conviction. 21 CFR Part 11 compliance, HIPAA, REMS protocol complexity means 18+ months to revenue-ready infrastructure. 2-year-to-revenue play.
KILLED — HISTORICAL DUPLICATE. Direct match found: 'Consumer Patient-Held Cell & Gene Therapy Cohort Outcome Registry' (20260417-0914-crossdomain, earlier today). Same customer (CGT-treated patient), same data, same paid buyer (sponsor RWE team), same multi-therapy aggregation premise. REMS framing is not a product differentiation.
Kill Reason
Historical duplicate of 'Consumer Patient-Held Cell & Gene Therapy Cohort Outcome Registry' produced earlier today in the morning flavor session (20260417-0914-crossdomain). Same customer, same data, same paid buyer, same multi-therapy aggregation thesis. The REMS framing is a labelling difference, not a product difference.
Risk Analysis
Risk analysis available for latest engine ideas.
What do you think?
Related ideas you can explore free:
killed: MyLynx (Series A $9M 2024) targets CGT treatment centers as its customer, with Memorial Sloan Kettering and Dana-Farber as reference accounts. MyLynx handles patient outreach, adverse-event capture, and post-dose monitoring — and can extend to cohort-comparison dashboards in one product cycle. With MyLynx holding the CGT-center channel, the distribution path is effectively closed. HIPAA plus CA GINA and Illinois GIPA genetic-privacy compliance is capital-intensive without venture scale.
killed: Open-source middleware (HAMi) already provides heterogeneous AI computing virtualization for free. Proprietary play is squeezed between free open-source and vertically integrated hardware vendor ecosystem.
killed: 5+ funded competitors including Cast AI ($1B valuation), OneChronos (backed by Nobel laureate), Akash Network (decentralized, 80% cheaper), Argentum AI (blockchain-settled). Market is claimed with massive capital.